Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
|ClinicalTrials.gov Identifier: NCT00162799|
Recruitment Status : Completed
First Posted : September 13, 2005
Last Update Posted : June 23, 2006
|Condition or disease||Intervention/treatment||Phase|
|Insulin Resistance||Drug: Triflusal (DCI)||Phase 2|
Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal, placebo-controlled.
Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days placebo, 15 days
Washout period: 30 days
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||30 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity|
|Study Start Date :||July 2002|
|Study Completion Date :||December 2004|
- Increase of insulin sensitivity in apparently healthy men and woman evaluate by means of i.v. glucose tolerance test (PTEVGMR).
- Reduction antropometric measures associated with insulin resistance and arterial hypertension.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00162799
|Unitat de Diabetologia, Endocrinologia y Nutrición Hosp Josep Trueta|
|Girona, Spain, 17007|
|Principal Investigator:||Jose Manuel Fernández del Real, Dr||Unidad Diabetología. Serv Endocrino Hosp Josep Trueta|